Friday, May 27, 2022 8:23:55 AM
"The NIH extended trial diverts our attention from the progress the Big Pharmas are making getting their mAbs into clinical trials. Another year, or less, of NIH trial testing could mean we lose our ability to maintain CMC compliance, if we can't financially reserve manufacturing capacity, maintain distribution agreements, or fulfill customer demand. It could mean that the FDA approves a Big Pharma mAb, and closes the EUA door.
Our fate is being wrested from us, with the successful completion of our internal Phase III trial, as the government attempts to commandeer our future...
Why would we need a larger patient population if a p value of 0.0003 and a Hazard Ratio of 2.96, can be obtained in a subset of that trial?"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165875890&txt2find=commandeer
That was 8 months ago. Things have now changed in our favor. The NIH trial is completed and most likely confirmatory of our LIVE-AIR results. There are now more variants, and billions of dollars worth of Covid products the government has purchased are useless.
You seem equally assured of our failure now, as you always have been.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM